ArticleCellular and molecular bioengineering2024

Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells.

Matthew D Poskus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.